| scholarly article | Q13442814 |
| P2093 | author name string | Colvin RB | |
| Tolkoff-Rubin NE | |||
| Schneeberger EE | |||
| Collins AB | |||
| Williams WW | |||
| Mauiyyedi S | |||
| Pascual M | |||
| Saidman S | |||
| Cosimi AA | |||
| Pelle PD | |||
| P433 | issue | 3 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 574-582 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries | |
| P478 | volume | 12 |
| Q41849097 | Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. |
| Q35012455 | Antibodies reactive to non-HLA antigens in transplant glomerulopathy |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q36666906 | Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation |
| Q27692014 | Antibody-mediated rejection: emergence of animal models to answer clinical questions |
| Q36432935 | B Cells, Antibodies, and More |
| Q37602189 | B cells mediate chronic allograft rejection independently of antibody production |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q37042154 | C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts |
| Q43239536 | Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. |
| Q35922715 | Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection |
| Q34901573 | Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q37394650 | Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses |
| Q37974480 | Clinical role of the renal transplant biopsy |
| Q88907649 | Clinical significance of Th17 cells in kidney transplantation |
| Q36062030 | Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens |
| Q37367683 | Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. |
| Q35655757 | Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice |
| Q36204503 | De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction? |
| Q33551885 | De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection |
| Q41966451 | Detection of T and B cells specific complement-fixing alloantibodies using flow cytometry: A diagnostic approach for a resource limited laboratory. |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q37541912 | Eicosapentenoic Acid Attenuates Allograft Rejection in an HLA-B27/EGFP Transgenic Rat Cardiac Transplantation Model |
| Q35124576 | Emerging role of B cells in chronic allograft dysfunction |
| Q37315152 | Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival |
| Q37485481 | Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys |
| Q34534928 | Genotypic diversity of complement component C4 does not predict kidney transplant outcome |
| Q64226624 | Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy |
| Q36202286 | Human leukocyte antigen antibodies for monitoring transplant patients |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q36048241 | Infiltration of Macrophages Correlates with Severity of Allograft Rejection and Outcome in Human Kidney Transplantation |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q35153318 | Late kidney allograft loss: what we know about it, and what we can do about it |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q37441972 | Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection |
| Q46335702 | Morphologic Features and Clinical Impact of Arteritis Concurrent with Transplant Glomerulopathy |
| Q37662989 | Old game, new players: Linking classical theories to new trends in transplant immunology |
| Q35210278 | Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study |
| Q37058039 | Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. |
| Q35901211 | Peripheral deletion of mature alloreactive B cells induced by costimulation blockade |
| Q84484568 | Peritubular capillary basement membrane changes in chronic renal allograft rejection: Comparison of light microscopic and ultrastructural observations |
| Q28082746 | Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine |
| Q34423734 | Picking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluation |
| Q34124202 | Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation |
| Q34084853 | Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy |
| Q33722343 | Prolongation of Cardiac Allograft Survival by Endometrial Regenerative Cells: Focusing on B-Cell Responses |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q35659332 | Recent advances in renal transplantation: antibody-mediated rejection takes center stage |
| Q38709765 | Renal allograft pathology with C4d immunostaining in patients with graft dysfunction |
| Q64982205 | Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. |
| Q26864255 | Role of complement and NK cells in antibody mediated rejection |
| Q37704938 | The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. |
| Q33884782 | The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians |
| Q38003049 | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q37363951 | The role of antibodies in transplantation |
| Q36054757 | The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients |
| Q35620353 | Thioredoxin priming prolongs lung allograft survival by promoting immune tolerance |
| Q50063069 | Transplant glomerulopathy |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
| Q36677655 | Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. |
| Q33764407 | Urinary proteomic analysis of chronic allograft nephropathy |
| Q79979170 | [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions] |
| Q46035754 | [Current problems of kidney transplantation]. |
Search more.